A
Anumana
Developing and delivering ECG algorithms enabling early diagnosis and intervention
About Anumana
Anumana is a startup that is revolutionizing cardiac care with cutting-edge AI, industry-leading translational science, and deep electrophysiological data. Anumana's AI solutions enable earlier diagnosis of otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes. Anumana's algorithms and software have the potential to improve procedure accuracy, reduce procedure times, improve medication management, and improve patient safety and outcomes. Anumana has one of the world’s largest electrophysiological data and longitudinal patient history and outcomes in the world. This harmonized, cleaned, and validated dataset was developed from multi-year data partnerships with several health systems from Anumana’s parent company, nference. Anumana's research is conducted on this extensive data platform, and their ECG-AI and EGM-AI algorithms have been validated by over 75 peer-reviewed publications. Anumana is making a profit by providing their AI solutions to healthcare providers and hospitals, and they are different from other businesses in the same industry because they are leveraging cutting-edge AI, industry-leading translational science, and deep electrophysiological data to provide more accurate and timely diagnosis and interventions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 173
- Open positions
- 1
- Dealroom signal
- 59.8/100
- Industry
- Health, Enterprise Software
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Core AI, Spinout, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Nov 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2025 | — | — | Boston Scientific · Matrix Partners · Matrix Capital Management · NTT Venture Capital | ↗ |
| EARLY VCOther financing | Nov 2022 | $32M | $128M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Anumana is 9.7K monthly website visits, up 34.7% over the last three months. Anumana's team grew 13.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Subtle MedicalAI-powered software enhancing medical imaging speed and quality |
Menlo Park, United States | Operational | 83 | $78M | $132M |
 WearHealthAI Health Intelligence for a safer, healthier and productive working environment |
Bremen, Germany | Operational | |||
 Pieces TechSoftware which interprets patient data in real time |
Irving, United States | Acquired | |||
 KenSciKenSci offers Healthcare AI platfrom & prediction apps that work across Clinical workflows, Cost Mgmt & Hospital Ops. #DeathVsDataScience |
Seattle, United States | Acquired | |||
 PhysIQPersonalized data analytics platform for human physiology |
Chicago, United States | Operational | |||
 ArterysMedical Imaging Cloud Platform |
San Francisco, United States | Operational | |||
 IcometrixAI-powered software for quantitative brain scan analysis |
Leuven, Belgium | Acquired | |||
 Fabric GenomicsGlobal healthcare platform for genomic data analysis - Formerly Omicia |
San Francisco, United States | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
MedTech Innovator
Series A4 investors entered at this stage
Matrix Partners
Mayo Clinic
Matrix Capital Management
NTT Venture Capital
Series B and later1 investor entered at this stage
Boston Scientific
Other known investors1 additional known investor
Mayo Clinic College of Medicine and Science
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Anumana on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Anumana’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.